SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation

The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, a successful postpartum depression launch, and a promising pipeline. The planned Indivior merger aims to accelerate diversification and cash flow, supporting further R&D and M&A.Based on Supernus P…